188 related articles for article (PubMed ID: 37031300)
41. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor.
Wei LY; Wu ZX; Yang Y; Zhao M; Ma XY; Li JS; Yang DH; Chen ZS; Fan YF
Exp Cell Res; 2020 Mar; 388(2):111858. PubMed ID: 31972220
[TBL] [Abstract][Full Text] [Related]
42. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells.
Xu GW; Toth JI; da Silva SR; Paiva SL; Lukkarila JL; Hurren R; Maclean N; Sukhai MA; Bhattacharjee RN; Goard CA; Medeiros B; Gunning PT; Dhe-Paganon S; Petroski MD; Schimmer AD
PLoS One; 2014; 9(4):e93530. PubMed ID: 24691136
[TBL] [Abstract][Full Text] [Related]
43. Discovery of Novel Pyrazolo-pyridone DCN1 Inhibitors Controlling Cullin Neddylation.
Kim HS; Hammill JT; Scott DC; Chen Y; Min J; Rector J; Singh B; Schulman BA; Guy RK
J Med Chem; 2019 Sep; 62(18):8429-8442. PubMed ID: 31465221
[TBL] [Abstract][Full Text] [Related]
44. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.
Nawrocki ST; Griffin P; Kelly KR; Carew JS
Expert Opin Investig Drugs; 2012 Oct; 21(10):1563-73. PubMed ID: 22799561
[TBL] [Abstract][Full Text] [Related]
45. TAS4464, A Highly Potent and Selective Inhibitor of NEDD8-Activating Enzyme, Suppresses Neddylation and Shows Antitumor Activity in Diverse Cancer Models.
Yoshimura C; Muraoka H; Ochiiwa H; Tsuji S; Hashimoto A; Kazuno H; Nakagawa F; Komiya Y; Suzuki S; Takenaka T; Kumazaki M; Fujita N; Mizutani T; Ohkubo S
Mol Cancer Ther; 2019 Jul; 18(7):1205-1216. PubMed ID: 31092565
[TBL] [Abstract][Full Text] [Related]
46. Neddylation-Independent Activities of MLN4924.
Mao H; Sun Y
Adv Exp Med Biol; 2020; 1217():363-372. PubMed ID: 31898238
[TBL] [Abstract][Full Text] [Related]
47. Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Torka P; Kambhampati S; Chen L; Wang X; Chen C; Vuong D; Qin H; Muir A; Orand K; Borja I; Lynne Smith D; Herrera AF; Spurgeon SEF; Park B; Lewis LD; Hernandez-Ilizaliturri F; Xia Z; Danilov AV
Blood Cancer J; 2023 Jan; 13(1):9. PubMed ID: 36631449
[TBL] [Abstract][Full Text] [Related]
48. Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic target.
Gao Q; Yu GY; Shi JY; Li LH; Zhang WJ; Wang ZC; Yang LX; Duan M; Zhao H; Wang XY; Zhou J; Qiu SJ; Jeong LS; Jia LJ; Fan J
Oncotarget; 2014 Sep; 5(17):7820-32. PubMed ID: 25229838
[TBL] [Abstract][Full Text] [Related]
49. NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells.
Kittai AS; Danilova OV; Lam V; Liu T; Bruss N; Best S; Fan G; Danilov AV
Oncotarget; 2021 Sep; 12(20):2068-2074. PubMed ID: 34611480
[TBL] [Abstract][Full Text] [Related]
50. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation.
Li X; Pham V; Tippin M; Fu D; Rendon R; Song L; Uchio E; Hoang BH; Zi X
Cell Commun Signal; 2019 Mar; 17(1):25. PubMed ID: 30885218
[TBL] [Abstract][Full Text] [Related]
51. Quantitative analyses for effects of neddylation on CRL2
Wang K; Reichermeier KM; Liu X
Protein Sci; 2021 Nov; 30(11):2338-2345. PubMed ID: 34459035
[TBL] [Abstract][Full Text] [Related]
52. Protein neddylation and its alterations in human cancers for targeted therapy.
Zhou L; Zhang W; Sun Y; Jia L
Cell Signal; 2018 Apr; 44():92-102. PubMed ID: 29331584
[TBL] [Abstract][Full Text] [Related]
53. The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors.
Vanderdys V; Allak A; Guessous F; Benamar M; Read PW; Jameson MJ; Abbas T
Mol Cancer Ther; 2018 Feb; 17(2):368-380. PubMed ID: 28838998
[TBL] [Abstract][Full Text] [Related]
54. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer.
Soucy TA; Smith PG; Rolfe M
Clin Cancer Res; 2009 Jun; 15(12):3912-6. PubMed ID: 19509147
[TBL] [Abstract][Full Text] [Related]
55. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Swords RT; Erba HP; DeAngelo DJ; Bixby DL; Altman JK; Maris M; Hua Z; Blakemore SJ; Faessel H; Sedarati F; Dezube BJ; Giles FJ; Medeiros BC
Br J Haematol; 2015 May; 169(4):534-43. PubMed ID: 25733005
[TBL] [Abstract][Full Text] [Related]
56. Nedd8-activating enzyme inhibitor MLN4924 (Pevonedistat), inhibits miR-1303 to suppress human breast cancer cell proliferation via targeting p27
Chen Y; Du M; Yusuying S; Liu W; Tan Y; Xie P
Exp Cell Res; 2020 Jul; 392(2):112038. PubMed ID: 32360865
[TBL] [Abstract][Full Text] [Related]
57. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.
Soucy TA; Smith PG; Milhollen MA; Berger AJ; Gavin JM; Adhikari S; Brownell JE; Burke KE; Cardin DP; Critchley S; Cullis CA; Doucette A; Garnsey JJ; Gaulin JL; Gershman RE; Lublinsky AR; McDonald A; Mizutani H; Narayanan U; Olhava EJ; Peluso S; Rezaei M; Sintchak MD; Talreja T; Thomas MP; Traore T; Vyskocil S; Weatherhead GS; Yu J; Zhang J; Dick LR; Claiborne CF; Rolfe M; Bolen JB; Langston SP
Nature; 2009 Apr; 458(7239):732-6. PubMed ID: 19360080
[TBL] [Abstract][Full Text] [Related]
58. MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma.
Tong S; Si Y; Yu H; Zhang L; Xie P; Jiang W
Sci Rep; 2017 Jul; 7(1):5599. PubMed ID: 28717191
[TBL] [Abstract][Full Text] [Related]
59. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
[TBL] [Abstract][Full Text] [Related]
60. The NEDD8 Conjugation Pathway and Its Relevance in Cancer Biology and Therapy.
Soucy TA; Dick LR; Smith PG; Milhollen MA; Brownell JE
Genes Cancer; 2010 Jul; 1(7):708-16. PubMed ID: 21779466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
